GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mydecine Innovations Group Inc (OTCPK:MYCOF) » Definitions » Cyclically Adjusted PB Ratio

Mydecine Innovations Group (Mydecine Innovations Group) Cyclically Adjusted PB Ratio : 0.00 (As of Apr. 29, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Mydecine Innovations Group Cyclically Adjusted PB Ratio?

As of today (2024-04-29), Mydecine Innovations Group's current share price is $0.0038. Mydecine Innovations Group's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2023 was $6.35. Mydecine Innovations Group's Cyclically Adjusted PB Ratio for today is 0.00.

The historical rank and industry rank for Mydecine Innovations Group's Cyclically Adjusted PB Ratio or its related term are showing as below:

During the past years, Mydecine Innovations Group's highest Cyclically Adjusted PB Ratio was 0.01. The lowest was 0.00. And the median was 0.00.

MYCOF's Cyclically Adjusted PB Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.76
* Ranked among companies with meaningful Cyclically Adjusted PB Ratio only.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Mydecine Innovations Group's adjusted book value per share data for the three months ended in Sep. 2023 was $-0.107. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $6.35 for the trailing ten years ended in Sep. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Mydecine Innovations Group Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Mydecine Innovations Group's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mydecine Innovations Group Cyclically Adjusted PB Ratio Chart

Mydecine Innovations Group Annual Data
Trend Dec13 Aug14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Mydecine Innovations Group Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 0.01

Competitive Comparison of Mydecine Innovations Group's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Mydecine Innovations Group's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mydecine Innovations Group's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mydecine Innovations Group's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Mydecine Innovations Group's Cyclically Adjusted PB Ratio falls into.



Mydecine Innovations Group Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Mydecine Innovations Group's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.0038/6.35
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mydecine Innovations Group's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2023 is calculated as:

For example, Mydecine Innovations Group's adjusted Book Value per Share data for the three months ended in Sep. 2023 was:

Adj_Book=Book Value per Share/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=-0.107/125.2304*125.2304
=-0.107

Current CPI (Sep. 2023) = 125.2304.

Mydecine Innovations Group Quarterly Data

Book Value per Share CPI Adj_Book
201311 0.000 97.182 0.000
201402 0.000 98.051 0.000
201405 -0.305 99.394 -0.384
201408 -1.160 99.315 -1.463
201412 4.679 98.367 5.957
201503 1.225 99.789 1.537
201506 33.321 100.500 41.520
201509 24.197 100.421 30.175
201512 -4.081 99.947 -5.113
201603 -8.391 101.054 -10.399
201606 -11.002 102.002 -13.507
201609 -14.552 101.765 -17.908
201612 21.065 101.449 26.003
201703 20.034 102.634 24.445
201706 14.818 103.029 18.011
201709 15.588 103.345 18.889
201712 12.617 103.345 15.289
201803 23.742 105.004 28.315
201806 -6.597 105.557 -7.827
201809 19.608 105.636 23.245
201812 0.369 105.399 0.438
201903 20.812 106.979 24.363
201906 17.292 107.690 20.108
201909 26.425 107.611 30.752
201912 2.075 107.769 2.411
202003 10.605 107.927 12.305
202006 3.851 108.401 4.449
202009 2.312 108.164 2.677
202012 0.786 108.559 0.907
202103 3.278 110.298 3.722
202106 2.747 111.720 3.079
202109 0.000 112.905 0.000
202112 0.032 113.774 0.035
202203 -0.545 117.646 -0.580
202206 -0.174 120.806 -0.180
202209 -0.273 120.648 -0.283
202212 -0.178 120.964 -0.184
202303 -0.273 122.702 -0.279
202306 -0.258 124.203 -0.260
202309 -0.107 125.230 -0.107

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Mydecine Innovations Group  (OTCPK:MYCOF) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Mydecine Innovations Group Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Mydecine Innovations Group's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Mydecine Innovations Group (Mydecine Innovations Group) Business Description

Traded in Other Exchanges
Address
789 West Pender Street, Suite 810, Vancouver, BC, CAN, V6C 1H2
Mydecine Innovations Group Inc is a biopharma and life sciences company engaged in the research, drug development, and clinical trials of psilocybin products.

Mydecine Innovations Group (Mydecine Innovations Group) Headlines